Syncromune
Manufacturing · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2919 E Commercial Blvd, Fort Lauderdale,...Website
www.syncromune.comRevenue
<$5 MillionIndustry
About Syncromune
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a novel and personalized in situ therapy that combines partial tumor oncolysis and a multi-target biologic drug. The SYNC-T combination approach is designed to target multiple mechanisms of cancer, promoting in situ immune activation while battling immunosuppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body and defend with immune memory. The first two candidates, SV-101 and SV-102, are currently in Phase 1 trials.Explore more
Syncromune Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Syncromune
Compare insights from companies similar to Syncromune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Syncromune Tech Stack
A closer look at the technologies used by Syncromune
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Syncromune
Sign Up For FreeTo access detailed company insights
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a novel and personalized in situ therapy that combi... Read More
